RAF inhibitors combined with asciminib can treat acute myeloid leukemia (AML) with BCR-ABL-TKI resistance.113 The ERK inhibitor, ulixertinib, combined with dasatinib synergistically expedited NB cell death.114 Furthermore, the combination of MEK inhibitors and TKIs receives the most attention. Here, MAP2K7 is linked to acute myeloid leukemia.